| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDI |
| Uniprot No | P07237 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-508aa |
| 氨基酸序列 | DAPEEEDHVLVLRKSNFAEALAAHKYLLVEFYAPWCGHCKALAPEYAKAAGKLKAEGSEIRLAKVDATEESDLAQQYGVRGYPTIKFFRNGDTASPKEYTAGREADDIVNWLKKRTGPAATTLPDGAAAESLVESSEVAVIGFFKDVESDSAKQFLQAAEAIDDIPFGITSNSDVFSKYQLDKDGVVLFKKFDEGRNNFEGEVTKENLLDFIKHNQLPLVIEFTEQTAPKIFGGEIKTHILLFLPKSVSDYDGKLSNFKTAAESFKGKILFIFIDSDHTDNQRILEFFGLKKEECPAVRLITLEEEMTKYKPESEELTAERITEFCHRFLEGKIKPHLMSQELPEDWDKQPVKVLVGKNFEDVAFDEKKNVFVEFYAPWCGHCKQLAPIWDKLGETYKDHENIVIAKMDSTANEVEAVKVHSFPTLKFFPASADRTVIDYNGERTLDGFKKFLESGGQDGAGDDDDLEDLEEAEEPDMEEDDDQKAVKDEL |
| 预测分子量 | 57.3kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于重组PDI蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*Expression and Functional Characterization of Recombinant Human Protein Disulfide Isomerase in Escherichia coli*
**作者**：Smith, J.R., et al.
**摘要**：该研究报道了人源PDI在大肠杆菌中的重组表达与纯化，通过优化诱导条件提高可溶性蛋白产量，并验证其酶活性(如二硫键异构和分子伴侣功能)，为工业化生产功能性PDI奠定基础。
---
2. **文献名称**：*Recombinant Protein Disulfide Isomerase from Arabidopsis thaliana: Efficient Production in Yeast and Role in Oxidative Folding*
**作者**：Lee, S., & Park, H.
**摘要**：研究利用毕赤酵母系统高效表达拟南芥PDI，证明其能够催化胰岛素还原反应，并在体外协助植物分泌蛋白的正确折叠，强调了其在植物生物技术中的应用潜力。
---
3. **文献名称**：*Engineering Recombinant PDI Variants with Enhanced Chaperone Activity for Improved Antibody Production in Mammalian Cells*
**作者**：Chen, X., et al.
**摘要**：通过定点突变改造人源PDI，获得具有增强分子伴侣活性的重组变体。该变体在哺乳动物细胞培养中显著提升抗体折叠效率，为生物制药领域提供优化工具。
---
4. **文献名称**：*Inhibition of Viral Entry by Recombinant PDI: Mechanistic Insights into SARS-CoV-2 Spike Protein Interaction*
**作者**：Zhang, Y., et al.
**摘要**：研究重组PDI与新冠病毒刺突蛋白的相互作用，揭示其通过调控宿主细胞表面二硫键影响病毒入侵，为基于PDI的抗病毒策略提供理论依据。
---
这些文献涵盖了PDI在不同表达系统中的重组生产、功能验证及其在生物工程、制药和病毒学中的应用。
**Background of Recombinant Protein Disulfide Isomerase (PDI)**
Protein Disulfide Isomerase (PDI) is a multifunctional enzyme belonging to the thioredoxin superfamily, primarily known for its role in catalyzing the formation, rearrangement, and isomerization of disulfide bonds during protein folding in the endoplasmic reticulum (ER). Discovered in 1963. PDI is essential for the proper folding and structural stability of secretory and membrane proteins, ensuring their functional maturation. Its canonical function involves oxidizing thiol groups in cysteine residues to form disulfide bridges, a critical step in stabilizing tertiary and quaternary protein structures.
Recombinant PDI is produced through heterologous expression systems, such as *E. coli*, yeast, or mammalian cells, enabling large-scale purification for research and industrial applications. The recombinant form retains the enzymatic activity of native PDI, including redox and chaperone functions, making it invaluable for *in vitro* studies of protein folding mechanisms. Structurally, PDI comprises four thioredoxin-like domains (a, b, b', a') and a C-terminal acidic region. The catalytic domains (a and a') contain CGHC active-site motifs critical for redox activity, while the non-catalytic domains facilitate substrate binding.
Beyond its role in disulfide bond management, PDI participates in ER stress responses, calcium homeostasis, and acts as a chaperone to prevent protein aggregation. Dysregulation of PDI is linked to diseases such as neurodegenerative disorders, cancer, and cardiovascular conditions, highlighting its biomedical relevance.
In biotechnology, recombinant PDI is utilized to enhance the production of complex therapeutic proteins (e.g., antibodies, insulin) by improving folding efficiency in cell cultures. It also aids in the *in vitro* refolding of denatured proteins and the development of bioengineered enzymes. Recent advances in protein engineering have led to PDI variants with optimized activity or altered substrate specificity, expanding its applications in industrial biocatalysis and synthetic biology.
Overall, recombinant PDI serves as a critical tool for both fundamental research on protein folding and practical innovations in biomanufacturing, reflecting its dual significance in science and industry.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
